The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
With 267 million tobacco users, improving access to evidence-based cessation tools is seen as critical
Under the new policy, financial assistance has been increased to Rs 50 lakh per patient to improve treatment access
VESCOP, ENTOD Pharmaceuticals, and APTI-MSB host the event to bridge lab-to-clinic gap in eye care
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
Genome editing holds extraordinary promise for treating previously incurable genetic diseases
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
The event showcased latest breakthroughs in minimally invasive surgery, organ-preservation strategies, and targeted therapies
The new capital is expected to fund the company through 2029
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
Subscribe To Our Newsletter & Stay Updated
